Just three months after scoring an accelerated FDA approval for Ojemda, Day One Biopharmaceuticals is teaming up with another fellow oncology specialist to grow the medicine’s global reach.

Thursday, Day One and Ipsen unveiled an ex-U.S. licensing agreement for tovorafenib (approved as Ojemda in the U.S.) in pediatric low-grade glioma (pLGG) and “any future indications developed by Day One.”

Source: With $111M upfront investment, Ipsen secures ex-US rights to Day One’s pediatric cancer med

Facebook
Twitter
LinkedIn
Connect With Us
BraveHearts for Kids Illinois
1879 N. Neltnor Blvd., Suite 105
West Chicago, IL 60185
630-473-4032
Join Our Email List
Receive news, research and event information.
© 2008- 2024 BraveHearts for Kids | Legal Notice and Privacy Policy
IRS Approved 501 (c) 3 Public Charity EIN 270660252